STOCK TITAN

Neogenomics Inc - NEO STOCK NEWS

Welcome to our dedicated page for Neogenomics news (Ticker: NEO), a resource for investors and traders seeking the latest updates and insights on Neogenomics stock.

Overview of NeoGenomics Inc

NeoGenomics Inc is a dedicated provider of oncology diagnostic testing and consultative laboratory services, specializing in cancer diagnosis and molecular oncology. The company focuses on offering high-quality, specialized laboratory tests and expert clinical interpretations from licensed physicians and molecular pathology experts. With a robust network of testing laboratories in both the United States and the United Kingdom, NeoGenomics is positioned to deliver critical support to pathologists and oncologists through a comprehensive suite of cancer-centric diagnostic services.

Core Business Segments and Services

NeoGenomics operates at the intersection of technical laboratory services and professional interpretive support. The core services include:

  • Oncology Diagnostics: Covering a wide array of cancer testing services including cytogenetics, hematologic and solid tumor fluorescent in situ hybridization (FISH) testing, and immunohistochemistry (IHC) supported by a comprehensive antibody library.
  • Molecular Oncology Testing: Featuring an extensive panel of molecular tests, including advanced next-generation sequencing (NGS) techniques, designed to profile biomarkers and genetic alterations pertinent to cancer diagnosis.
  • Technical and Professional Consulting: Providing on-demand training and interpretive services, ensuring that technical testing interfaces seamlessly with clinical decision-making processes.
  • Rapid Test Development: Employing an agile testing methodology to quickly incorporate new technologies and biomarkers into its diagnostic panels.

Significance in the Oncology Diagnostic Landscape

NeoGenomics has carved out a niche within the highly specialized field of cancer diagnostics by emphasizing precision, efficiency, and an integrated approach to laboratory testing. The company has built its reputation on offering some of the industry's fastest turnaround times and the most diverse technical-only services geared towards highly complex cancer testing. By effectively bridging technical laboratory operations with professional consultative services, NeoGenomics meets the diverse needs of healthcare providers who require reliable, accurate, and timely diagnostic information.

Operational Excellence and Industry Expertise

Central to NeoGenomics’ value proposition is its commitment to excellence in both technical execution and interpretive expertise. The company has focused on building a resilient network that supports:

  • Diagnostic Accuracy and Efficiency: Extensive technical protocols and quality control measures are in place to ensure that test results are delivered with unmatched accuracy and reliability.
  • Expert Consultation: Licensed physicians and specialist molecular experts support clinicians by providing detailed interpretations, ensuring that diagnostic results are effectively integrated into patient management decisions.
  • Adaptability and Innovation: With one of the most agile test development cycles in the industry, NeoGenomics continually evolves its diagnostic panels to incorporate emerging biomarkers and novel testing strategies.

Competitive Landscape and Differentiation

Within the competitive landscape of diagnostic laboratories, NeoGenomics differentiates itself by combining comprehensive technical testing with high-caliber professional interpretation. Unlike facilities that solely focus on technical aspects, NeoGenomics offers a blended model that addresses both the technical and clinical dimensions of cancer diagnostics. This dual approach not only enhances the overall quality of patient care but also provides healthcare providers with a robust framework for making informed clinical decisions.

Comprehensive Service Offerings and Client Impact

The operational model at NeoGenomics is designed around serving the needs of cancer-focused healthcare providers such as pathologists and oncologists. The company’s expertise in both high-complexity laboratory testing and interpretive consultation ensures that its services are well-integrated into the broader framework of cancer care. By continuously expanding their technological and diagnostic capabilities, they provide an evergreen resource that keeps pace with advancements in cancer research and treatment protocols.

Conclusion

NeoGenomics Inc stands out as an essential partner in the oncology diagnostic arena. Through a blend of advanced technical laboratory services and seasoned clinical interpretation, the company supports more accurate, timely, and clinically relevant cancer diagnosis. Its commitment to quality, fast turnaround times, and a wide-ranging test menu reinforces its position as a central figure in ensuring that healthcare professionals have the reliable diagnostic information they need to better manage patient care.

Rhea-AI Summary

NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 10:50 AM ET. CFO Kathryn McKenzie and Chief Strategy Officer Doug Brown will discuss the company's cancer-focused genetic testing services. The presentation will be available via webcast on the company's website. NeoGenomics specializes in oncology testing and supports pharmaceutical clients in clinical trials. The company operates multiple accredited laboratories across the U.S. and internationally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.32%
Tags
conferences
-
Rhea-AI Summary

NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 10:00 AM ET. Key executives, including CEO Douglas VanOort and CFO Kathryn McKenzie, will be involved in the presentation. The event will be webcast live, accessible via the company’s investor relations page. NeoGenomics specializes in cancer genetic testing and serves a wide range of healthcare providers and pharmaceutical firms globally. For more information, visit www.neogenomics.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
conferences
-
Rhea-AI Summary

NeoGenomics reported a record revenue of $126 million for Q4 2020, an 18% increase year-over-year. Clinical Services revenue rose 14% to $107 million, boosted by $9 million in COVID-19 testing. Pharma Services revenue surged 43% to $19 million with a backlog growth of 60% to $209 million. Although net income for 2020 declined to $4 million from $8 million in 2019, adjusted EBITDA fell to $35 million from $57 million. The company completed stock and convertible note offerings, generating $553 million for corporate growth and acquisitions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
News
Rhea-AI Summary

NeoGenomics, Inc. announces a leadership transition with Mark Mallon set to become CEO on April 19, 2021, succeeding Douglas M. VanOort, who will assume the role of executive chairman. VanOort, who led the company for 12 years, helped grow revenues from $20 million to approximately $500 million, and increased market capitalization from $26 million to over $6 billion. Mallon, previously CEO of Ironwood Pharmaceuticals, brings extensive experience from AstraZeneca. The change aims to build on NeoGenomics' strong competitive position in oncology testing and enhance value for stakeholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
-
Rhea-AI Summary

NeoGenomics, Inc. (NASDAQ:NEO) will participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference on February 19, 2021 at 9:30am ET. Presenters include CEO Douglas VanOort, CFO Kathryn McKenzie, and Chief Strategy Officer Doug Brown. The event will be available via live webcast on the company's investor relations website. NeoGenomics specializes in cancer genetics testing and provides comprehensive services for diagnostics and drug development for various healthcare entities worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences
-
Rhea-AI Summary

NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its fourth quarter and full year 2020 financial results on February 24, 2021. A conference call to discuss these results is scheduled for 8:30 AM EDT on the same day. Investors can access the call by dialing the provided numbers. NeoGenomics specializes in cancer genetics testing and offers comprehensive oncology-focused testing services. The Company operates accredited laboratories across the U.S., Switzerland, and Singapore, serving a variety of healthcare entities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
Rhea-AI Summary

Parexel and NeoGenomics have announced a strategic partnership aimed at enhancing oncology clinical trials through the application of real-world genomic data. This collaboration will facilitate better patient matching and optimize trial design by identifying genomic mutations and linking patient data with clinical datasets. The partnership seeks to accelerate patient enrollment in clinical trials and improve treatment outcomes. Both companies aim to expand their relationship in the oncology space by exploring advancements in lab services and biomarker capabilities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
-
Rhea-AI Summary

The Access to Comprehensive Genomic Profiling Coalition has welcomed NeoGenomics (NASDAQ: NEO) and Tempus, emphasizing advocacy for broad U.S. insurance coverage of comprehensive genomic profiling (CGP) for advanced cancer patients. NeoGenomics offers extensive cancer diagnostics and services, while Tempus utilizes AI to enhance precision medicine efforts. Both companies aim to improve patient outcomes through better access to CGP, which informs treatment decisions. The coalition will also engage insurers to highlight the clinical and economic benefits of CGP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
none
-
Rhea-AI Summary

NeoGenomics announced the pricing of public offerings of 4,081,632 shares of common stock at $49.00 per share, aiming for gross proceeds of $200 million, and $300 million in 0.25% convertible senior notes due 2028. The offerings are set to close around January 11, 2021. The convertible notes have an initial conversion price of approximately $66.15 per share, with a conversion premium of 35%. Proceeds will be utilized for general corporate purposes and potential investments. Underwriters have a 30-day option to purchase additional shares and notes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
Rhea-AI Summary

NeoGenomics, Inc. has announced public offerings of approximately $200 million in common stock and $250 million in convertible senior notes due 2028. The offerings are not contingent on each other and are subject to market conditions. The convertible notes will bear interest and can be converted into cash or shares based on specific circumstances. Funds will be utilized for general corporate purposes and capped call transactions, with potential investments in complementary businesses. Market reactions may vary based on derivatives transactions related to these offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.36%
Tags

FAQ

What is the current stock price of Neogenomics (NEO)?

The current stock price of Neogenomics (NEO) is $9.35 as of April 1, 2025.

What is the market cap of Neogenomics (NEO)?

The market cap of Neogenomics (NEO) is approximately 1.2B.

What core services does NeoGenomics Inc offer?

NeoGenomics offers comprehensive oncology diagnostic testing, including molecular oncology, cytogenetics, and advanced immunohistochemistry services alongside expert interpretive consultation by licensed physicians.

How does NeoGenomics support clinical decision-making?

By providing integrated laboratory testing with detailed clinical consultations and expert interpretations, NeoGenomics empowers pathologists and oncologists to make informed decisions based on precise diagnostic data.

What sets NeoGenomics apart in the diagnostic testing industry?

The company differentiates itself through its rapid test development, diverse technical-only testing capabilities, and the combination of technical excellence with professional consultation, ensuring high-quality and timely diagnostic results.

In which regions does NeoGenomics operate?

NeoGenomics operates a network of specialized laboratories in the United States and the United Kingdom, serving the needs of healthcare providers in these regions.

What types of diagnostic tests are performed at NeoGenomics?

They perform a wide range of tests including molecular oncology panels, next-generation sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC), along with other advanced cytogenetic and histopathologic analyses.

How does NeoGenomics ensure the accuracy and reliability of its tests?

Through stringent quality control protocols, rapid test development cycles, and the expertise of licensed physicians and molecular experts, NeoGenomics maintains high diagnostic accuracy and reliability.

What benefits do clients gain from NeoGenomics' technical-only testing programs?

Clients benefit from on-demand training, live support for technical tests, and access to an extensive menu of specialized testing services that are integrated with expert consultation, enhancing overall diagnostic efficiency.

How does NeoGenomics compare to similar diagnostic laboratories?

NeoGenomics distinguishes itself by combining advanced technological capabilities with dedicated clinical consultation, offering a more integrated approach compared to laboratories that may focus solely on technical testing.
Neogenomics Inc

NASDAQ:NEO

NEO Rankings

NEO Stock Data

1.21B
126.92M
1.23%
102.53%
2.71%
Diagnostics & Research
Services-testing Laboratories
Link
United States
FORT MYERS